Everolimus (Certican) in heart transplantation: Optimizing renal function through minimizing cyclosporine exposure

H. Lehmkuhl, H. Ross, Howard Eisen, H. Valantine

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The proliferation signal inhibitor everolimus is efficacious for reducing the incidence of acute rejection and cardiac allograft vasculopathy (CAV) in heart transplantation; and it has the potential to facilitate cyclosporine (CsA) minimization in this setting. Reducing CsA dose in heart transplantation is dependent on everolimus trough blood levels of 3 to 8 ng/mL being achieved. Physicians experienced in the use of everolimus aim for CsA trough blood levels of 175 to 200 ng/mL in everolimus-treated patients during the initial 3 months following heart transplantation. Modeling data from the heart pivotal study suggest that CsA trough blood levels of 100 ng/mL at 6 months posttransplant could be targeted without loss of efficacy, and antibody induction therapy may assist with this approach. Target CsA trough blood levels for maintenance patients could possibly be reduced from the current 80 to 100 ng/mL to 50 to 80 ng/mL. Maintenance patients with renal dysfunction or CAV may benefit from conversion to everolimus and subsequent reduction in CsA trough blood levels (eg, by 50%). Initial experience of everolimus with reduced CsA trough blood levels in heart transplantation is favorable, but there is scope for further study.

Original languageEnglish (US)
Pages (from-to)4145-4149
Number of pages5
JournalTransplantation proceedings
Volume37
Issue number10
DOIs
StatePublished - Dec 1 2005

Fingerprint

Heart Transplantation
Cyclosporine
Kidney
Allografts
Everolimus
Physicians
Antibodies
Incidence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

@article{379997f96c614971bd31d9b3bc67847a,
title = "Everolimus (Certican) in heart transplantation: Optimizing renal function through minimizing cyclosporine exposure",
abstract = "The proliferation signal inhibitor everolimus is efficacious for reducing the incidence of acute rejection and cardiac allograft vasculopathy (CAV) in heart transplantation; and it has the potential to facilitate cyclosporine (CsA) minimization in this setting. Reducing CsA dose in heart transplantation is dependent on everolimus trough blood levels of 3 to 8 ng/mL being achieved. Physicians experienced in the use of everolimus aim for CsA trough blood levels of 175 to 200 ng/mL in everolimus-treated patients during the initial 3 months following heart transplantation. Modeling data from the heart pivotal study suggest that CsA trough blood levels of 100 ng/mL at 6 months posttransplant could be targeted without loss of efficacy, and antibody induction therapy may assist with this approach. Target CsA trough blood levels for maintenance patients could possibly be reduced from the current 80 to 100 ng/mL to 50 to 80 ng/mL. Maintenance patients with renal dysfunction or CAV may benefit from conversion to everolimus and subsequent reduction in CsA trough blood levels (eg, by 50{\%}). Initial experience of everolimus with reduced CsA trough blood levels in heart transplantation is favorable, but there is scope for further study.",
author = "H. Lehmkuhl and H. Ross and Howard Eisen and H. Valantine",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.transproceed.2005.10.005",
language = "English (US)",
volume = "37",
pages = "4145--4149",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

Everolimus (Certican) in heart transplantation : Optimizing renal function through minimizing cyclosporine exposure. / Lehmkuhl, H.; Ross, H.; Eisen, Howard; Valantine, H.

In: Transplantation proceedings, Vol. 37, No. 10, 01.12.2005, p. 4145-4149.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Everolimus (Certican) in heart transplantation

T2 - Optimizing renal function through minimizing cyclosporine exposure

AU - Lehmkuhl, H.

AU - Ross, H.

AU - Eisen, Howard

AU - Valantine, H.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The proliferation signal inhibitor everolimus is efficacious for reducing the incidence of acute rejection and cardiac allograft vasculopathy (CAV) in heart transplantation; and it has the potential to facilitate cyclosporine (CsA) minimization in this setting. Reducing CsA dose in heart transplantation is dependent on everolimus trough blood levels of 3 to 8 ng/mL being achieved. Physicians experienced in the use of everolimus aim for CsA trough blood levels of 175 to 200 ng/mL in everolimus-treated patients during the initial 3 months following heart transplantation. Modeling data from the heart pivotal study suggest that CsA trough blood levels of 100 ng/mL at 6 months posttransplant could be targeted without loss of efficacy, and antibody induction therapy may assist with this approach. Target CsA trough blood levels for maintenance patients could possibly be reduced from the current 80 to 100 ng/mL to 50 to 80 ng/mL. Maintenance patients with renal dysfunction or CAV may benefit from conversion to everolimus and subsequent reduction in CsA trough blood levels (eg, by 50%). Initial experience of everolimus with reduced CsA trough blood levels in heart transplantation is favorable, but there is scope for further study.

AB - The proliferation signal inhibitor everolimus is efficacious for reducing the incidence of acute rejection and cardiac allograft vasculopathy (CAV) in heart transplantation; and it has the potential to facilitate cyclosporine (CsA) minimization in this setting. Reducing CsA dose in heart transplantation is dependent on everolimus trough blood levels of 3 to 8 ng/mL being achieved. Physicians experienced in the use of everolimus aim for CsA trough blood levels of 175 to 200 ng/mL in everolimus-treated patients during the initial 3 months following heart transplantation. Modeling data from the heart pivotal study suggest that CsA trough blood levels of 100 ng/mL at 6 months posttransplant could be targeted without loss of efficacy, and antibody induction therapy may assist with this approach. Target CsA trough blood levels for maintenance patients could possibly be reduced from the current 80 to 100 ng/mL to 50 to 80 ng/mL. Maintenance patients with renal dysfunction or CAV may benefit from conversion to everolimus and subsequent reduction in CsA trough blood levels (eg, by 50%). Initial experience of everolimus with reduced CsA trough blood levels in heart transplantation is favorable, but there is scope for further study.

UR - http://www.scopus.com/inward/record.url?scp=29544442185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29544442185&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2005.10.005

DO - 10.1016/j.transproceed.2005.10.005

M3 - Article

C2 - 16387066

AN - SCOPUS:29544442185

VL - 37

SP - 4145

EP - 4149

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -